Interferon beta-1 a in relapsing-remitting multiple sclerosis

Hospital Medicine

Volumn 60, Issue 3, 1999, Pages 192-195

  Blumhardt, Lance ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; IMMUNOLOGICAL ADJUVANT;

ADOLESCENT; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE;

EID: 0033090647     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.1999.60.3.1065     Document Type: Article

References (20)

1. Broderick JP, Samaha FJ (1994) Letter. Neurology 44: 186
2. Compston A (1995) Beta-interferon and multiple sclerosis: not a final solution to the problem. Br J Hasp Med 53: 547-53
3. Freedman MS and The Once Weekly Interferon for MS (OWIMS) Study Group. Interferon beta-la in multiple sclerosis: dose dependent clinical and MRI efficacy. 123rd Annual Meeting of the American Neurological Association (ANA) 18-21 October 1998, Montreal, Canada
4. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicentre, randomised, double-blind, placebo-controlled trial. Neurology 43: 655-61
5. Jacobs LD, Cookfair DL, Rudick RA et al. (1996) Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: 285-94
6. Johnson KP, Knobler RL, Greenstein JL et al. (1990) Recombinant human interferon beta treatment of relapsing-remitting multiple sclerosis. Neurology 40(suppl 1 ): 261A
7. Klapper JL ( 1994) Letter. Neurology 44: 188
8. Liu C, Li Wan Po A, Blumhardt LD (1998) 'Summary measure' statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neiirosurg Psvchiat 64: 726-9
9. Liu C, Edwards SGM, Gong Q, Roberts N, Blumhardt LD (1999) Three dimentional MRI estimated of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neiirosurg Psvchiatiy (in press)
10. Longstreth WT, Franklin GM ( 1994 ) Letter. Neurology 44: 188
11. McDonald CM. McDonald MA (1994) Letter. Neurology 44: 187
12. Metz L, Bell R, Zochodne D (1994) Letter. Neurohgv 44: 187-88
13. Mews I, Bergmann M, Bunkowski S, Gullotta F, Bruck M (1998) Oligodendrocyte and axon pathology in clinically silent multiple sclerosis. Multiple Sclerosis 4: 55-62
14. Mumford C (1996) Beta interferon and multiple sclerosis: why the fuss? Q J Med 89: 1 -3
15. Munafo A, Trinchard-Lugan I, Nguyen TXQ et al. (1998) Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-la after intramuscular and subcutaneous administration. Eur Neurol 5(2): 187-93
16. Noseworthy J (1997) Are placebo-controlled trials still ethical in multiple sclerosis? In: Thompson AJ, Polman C, Hohlfeld R, eds. Multiple Sclerosis: Clinical Challenges and Controversies. Martin Dunitz, London: 177-94
17. PRISMS (Prevention of Relapses and Disability by Interferon beta-la Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebocontrolled study of interferon beta-la in relapsing/remitting multiple sclerosis. Lancet 352: 1498-504
18. Scrip (1998) US MS society urges early drug treatment. Sm 2381:21
19. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. NEnglJMed 33,8: 278-85
20. Weinshenker BG, Bass B, Rice GPA (1989) The natural history of multiple sclerosis: a geographically based study -2, predictive value of the early clinical course. Brain 112: 1419-28